Melanocortin receptors: published research on Melanotan-II

The melanocortin receptor family comprises five G-protein coupled receptors (MC1R through MC5R), each displaying distinct tissue localisation and functional profiles in published research. These receptors are activated endogenously by α-melanocyte-stimulating hormone (α-MSH) and adrenocorticotropic hormone (ACTH), both derived from the pro-opiomelanocortin (POMC) precursor. The literature distinguishes between classical melanocortin signalling pathways—particularly those mediated by MC1R in melanocytes and MC4R in the hypothalamus—and more recently characterised peripheral distributions.

Structural studies demonstrate that melanocortin receptors share the characteristic seven-transmembrane topology of G-protein coupled receptors, with ligand-binding pockets formed by transmembrane helices and extracellular loops. Receptor selectivity and affinity vary substantially across the family, with implications for ligand design in research contexts. The published literature emphasises that small-molecule melanocortin agonists often exhibit different pharmacological profiles than endogenous peptide ligands, reflecting differences in binding kinetics and downstream signalling activation.

Melanotan-II (MT-II) is a synthetic cyclic α-melanocyte-stimulating hormone analogue investigated extensively in the research literature for its broad-spectrum melanocortin receptor binding properties. Published in vitro studies characterise MT-II as a non-selective agonist across multiple melanocortin receptor subtypes, demonstrating nanomolar to picomolar affinity constants depending on the receptor isoform and assay methodology employed.

The compound's structural design—incorporating a cyclic backbone and constrained geometry—has been the subject of structure–activity relationship (SAR) investigations, with researchers examining how modifications to the peptide scaffold alter receptor selectivity and binding kinetics. In cell-line receptor binding assays, MT-II exhibits potent activation of MC1R and MC4R, along with measurable affinity for MC3R and MC5R. The published literature notes that MT-II's broad receptor profile distinguishes it from more selective analogues, making it a valuable tool for understanding melanocortin signalling across multiple receptor contexts.

MC1R is the prototypical melanocortin receptor, localised to melanocytes and recognised as the primary determinant of constitutive and stimulated melanin synthesis in published cellular assays. In vitro research with melanocyte-derived cell lines demonstrates that MT-II binding to MC1R activates adenylyl cyclase via Gs protein coupling, elevating intracellular cyclic adenosine monophosphate (cAMP) concentrations and downstream effector signalling through protein kinase A (PKA).

Published literature shows that receptor occupancy by MT-II in these systems correlates with increased expression of microphthalmia-associated transcription factor (MITF) and upregulation of melanogenic enzyme activity. Comparative binding studies illustrate MC1R's preference for certain melanocortin agonists over others, with MT-II demonstrating high affinity but non-selective activation. The research literature emphasises that MC1R signalling outcomes depend critically on cellular context, receptor density, and the kinetics of ligand engagement, factors routinely controlled in standardised cell-line assays used by research laboratories.

MC4R is expressed predominantly in the hypothalamus and has emerged as a central node in melanocortin pathway research. Published studies of hypothalamic cell-line models demonstrate that MT-II activation of MC4R engages similar cAMP-dependent signalling cascades to those observed at MC1R, though with tissue-specific consequences. The literature distinguishes between pharmacological receptor occupancy studies and functional outcomes measured in integrated neuronal assays.

In vitro concentration-response studies have characterised MT-II binding to recombinant MC4R and native receptor populations in hypothalamic cells. The published research literature identifies MT-II as a pan-agonist across the melanocortin family, with particular potency at MC4R in many assay systems. Selectivity investigations using point-mutant receptors and chimeric receptor constructs have elucidated the molecular determinants of MT-II binding, contributing to understanding of structure–activity relationships within the melanocortin ligand class.

The published research literature contains numerous comparative binding studies evaluating MT-II affinity across melanocortin receptor subtypes. Radioligand competition assays, calcium mobilisation assays, and cAMP-accumulation assays represent the principal methodologies employed to characterise receptor pharmacology. These studies consistently show that MT-II exhibits measurable affinity at all five melanocortin receptors, though with concentration-dependent selectivity profiles that vary between assay platforms.

Structure–activity relationship investigations have examined the contribution of the cyclic backbone, aromatic residues, and charged amino acids to MT-II's receptor selectivity. The literature notes that truncation, cyclisation, and amino acid substitution within the MT-II scaffold generate analogues with improved selectivity for specific melanocortin receptor subtypes, findings that inform ongoing peptide chemistry research. Peptigen Labs supplies MT-II as a research material only, supporting in vitro studies and receptor characterisation projects within qualified laboratory settings.

In vitro investigations employing MT-II typically utilise stable cell lines expressing recombinant melanocortin receptors, primary cell cultures, or tissue preparations containing native receptor populations. Published protocols detail autosampler methods for quantifying receptor-ligand interactions via radioligand binding, fluorescence polarisation, and surface plasmon resonance (SPR) techniques. Researchers emphasise the importance of standardised buffer conditions, temperature control, and ligand concentration ranges when characterising MT-II binding kinetics.

The receptor pharmacology literature increasingly employs functional assays—measuring downstream signalling outcomes such as cAMP accumulation, intracellular calcium mobilisation, and phosphorylation of signalling intermediates—to contextualise binding affinity data. Published studies underscore the necessity of rigorous controls, including non-specific binding assessment, saturation analysis, and verification of receptor expression via Western blotting or immunocytochemistry. These methodological standards ensure reproducibility and reliability of MT-II characterisation data across research laboratories.